50 mg per dose for BSA = 1.25 m2 to < 1.5 m2

2 trials

Sponsors

Sun Yat-sen University Cancer Center

Conditions

Esophageal squamouse cell carcinoma

Phase 2

Neoadjuvant Camrelizumab Combined with Chemotherapy for Thoracic Esophageal Squamous Cell Carcinoma with Cervical Lymph Node Metastasis: A Single Arm Phase II Study.

Active, not recruitingChiCTR2500097269

Sun Yat-sen University Cancer CenterEsophageal squamouse cell carcinoma

Start: 2025-03-01Updated: 2025-02-24

Unknown Phase

Neoadjuvant Camrelizumab Combined with Chemotherapy for Elderly Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Single Arm, Multicenter Phase II Study.

Active, not recruitingChiCTR2500104016

Sun Yat-sen University Cancer CenterEsophageal squamouse cell carcinoma

Start: 2025-07-01Updated: 2025-06-16